Ontology highlight
ABSTRACT: Background
Conservative management of adnexal mass is warranted when there is imaging-based and clinical evidence of benign characteristics. Malignancy risk is, however, a concern due to the mortality rate of ovarian cancer. Malignancy occurs in 10-15% of adnexal masses that go to surgery, whereas the rate of malignancy is much lower in masses clinically characterized as benign or indeterminate. Additional diagnostic tests could assist conservative management of these patients. Here we report the clinical validation of OvaWatch, a multivariate index assay, with real-world evidence of performance that supports conservative management of adnexal masses.Methods
OvaWatch utilizes a previously characterized neural network-based algorithm combining serum biomarkers and clinical c
SUBMITTER: Reilly GP
PROVIDER: S-EPMC9900123 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature